<DOC>
	<DOCNO>NCT01283074</DOCNO>
	<brief_summary>This observational , multi-center , open-label study evaluate prognostic factor long-term-response safety Pegasys ( peginterferon alfa-2a ) patient HbeAg-negative chronic hepatitis B . Data collect 96 week .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Patients With HbeAg-negative Chronic Hepatitis B ( Perseas )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis HBeAgnegative chronic hepatitis B compensate hepatic disease , virus multiplication , raise alanine amino transferase result and/or fibrosis Coinfection hepatitis A , C D Coinfection human immunodeficiency virus ( HIV ) Severe hepatic dysfunction decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>